Boston, MA -- (SBWIRE) -- 03/07/2017 -- The immense growth potential in pharmerging market has driven large multinational pharmaceutical companies to focus on these regions by pursuing organic as well as in-organic routes. To make in-roads into the new geography, the large players usually take in-organic route through strategic expansion initiatives such as acquisitions and alliances. For instance, in December 2015, AstraZeneca entered into a deal with WuXi to acquire its biologics manufacturing facilities in China to expand locally.

Technavio's analysts forecast the global pharmerging market to grow at a CAGR of 12.88% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global pharmerging market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of pharmaceutical drugs in pharmerging markets, which are further divided into Tier I, II and III.

Get More Details on this Report and a Full Table of Contents at Global Pharmerging Markets 2017-2021

The market is divided into the following segments based on geography:

-Tier 1
-Tier 2
-Tier 3

Technavio's report, Global Pharmerging Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-AstraZeneca
-GlaxoSmithKline
-Pfizer
-Sanofi
-Novartis

Other prominent vendors

-Abbott Laboratories
-AbbVie
-Alexion Pharmaceuticals
-Allergan
-Amgen
-Aspen
-Astellas Pharma
-Baxter
-Bayer
-Biogen
-Boehringer Ingelheim
-Bristol-Myers Squibb
-Celgene
-CSL Behring
-Daiichi Sankyo
-Dainippon Sumitomo Pharma
-Eisai
-Eli Lilly
-Endo Health Pharmaceuticals
-F. Hoffmann-La Roche
-Fresenius
-Gilead
-Grifols
-H. Lundbeck
-Hospira
-Johnson & Johnson
-Kyowa Hakko Kirin
-Mallinckrodt Pharmaceuticals
-Menarini
-Mitsubishi Tanabe Pharma
-Mylan
-Novo Nordisk
-Otsuka
-Shire
-STADA Arzneimittel
-Sun Pharmaceutical
-Takeda Pharma
-Teva Pharmaceutical Industries
-UCB
-Valeant Pharmaceuticals

Market driver

-Limitations in developed economies fuels demand in emerging economies
-For a full, detailed list, view our report

Market challenge

-Stringent price control and generic -centric usage lead to value erosion
-For a full, detailed list, view our report

Market trend

-Potential of new countries in emerging markets
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2021 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

About Thoracic Surgery

Thoracic surgery involves surgical treatment (open surgery or minimally invasive surgery) to address medical conditions involving the heart or lungs. It includes procedures such as redo heart surgery, aortic dissection for aortic surgery, minimally invasive mitral valve repair and replacement, and endovascular repair of thoracic aortic aneurysms. It is performed to treat end-stage heart failure, heart-lung transplants, and placement of ventricular-assist devices.

Technavio's analysts forecast the global thoracic surgery market to grow at a CAGR of 10.16% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global thoracic surgery market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of medical devices required for thoracic surgeries.

The market is divided into the following segments based on geography:

-Americas
-APAC
-EMEA

Technavio's report, Global Thoracic Surgery Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-Boston Scientific
-Medtronic

Companies Mentioned in this Report: AstraZeneca, GlaxoSmithKline, Pfizer, Sanofi, Novartis, Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical Industries, UCB, Valeant Pharmaceuticals

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:
-Pharmaceutical Excipients Market - Global Forecast to 2021
-Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way
-Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market
-Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth
-Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market